Introduction
============

Glycosyltransferases represent a large family of enzymes that catalyse biosynthesis of oligosaccharides, polysaccharides, and glycoconjugates. Sugar moieties are transferred from activated sugar donors to specific acceptor molecules via the formation of glycosidic bonds ([@awz358-B7]). Acceptor molecules include other sugars, nucleic acids, lipids, and proteins. Glycosyltransferases reside predominantly within the Golgi apparatus of eukaryotes as type II transmembrane proteins. Over 90 glycosyltransferase families have been described ([www.cazy.org/GlycosylTransferases.html](http://www.cazy.org/GlycosylTransferases.html)). Sequence alignment tools have been useful for predicting glycosyltransferase function, including a metal-binding motif important for configuration of substrate within the active site ([@awz358-B30]). However, even closely related sequences have been shown to exhibit different catalytic activity ([@awz358-B6]). Glycosyltransferases are classified as either 'retaining' or 'inverting' enzymes according to whether the anomeric bond within the donor substrate is retained or inverted during the sugar transfer.

Neurodegenerative diseases are increasing in frequency, in part due to an ageing population. Despite this, neurodegenerative diseases represent a significant unmet health need without effective treatments or clearly delineated pathogenic mechanisms. Changes in expression levels of glycosyltransferases have been strongly linked with neurodegeneration ([@awz358-B34]; [@awz358-B12]; [@awz358-B43]), but determining whether these effects are upstream of neurotoxicity is difficult. Two distinct glycosyltransferase-associated mechanisms are prominent: ganglioside synthesis and addition of *O*-linked β-*N*-acetylglucosamine to proteins (*O*-GlcNAcylation). Major gangliosides are sialic acid-containing glycosphingolipids. Within the mammalian brain they are synthesized in the endoplasmic reticulum from a lactosylceramide precursor before remodelling during transit from the *cis*- to the *trans*-Golgi network by a series of glycosyltransferase enzymes ([Fig. 1](#awz358-F1){ref-type="fig"}). Mature gangliosides are expressed on the plasma membrane of most vertebrate cells and within bodily fluids. They are particularly abundant on neuronal and glial cells within the CNS where they are thought to function prominently in cell signalling ([@awz358-B46]). Altered levels of gangliosides have been reported in animal models of amyotrophic lateral sclerosis (ALS) and in post-mortem CNS tissue from ALS patients ([@awz358-B2]; [@awz358-B14]); similar findings have been reported in Parkinson's disease ([@awz358-B49]) and Alzheimer's disease ([@awz358-B20]). *O*-GlcNAcylation occurs predominantly in the brain and is regulated by the glycosyltransferases *O*-linked *N*-acetylglucosamine transferase (OGT) and EGF domain-specific *O*-linked *N*-acetylglucosamine transferase (EOGT), which attach the *O*-GlcNAc moiety to acceptor proteins at specific serine/threonine residues via an *O*-linked glycosidic bond. OGT acts intracellularly whereas EOGT acts extracellularly on secreted and membrane proteins ([Fig. 2](#awz358-F2){ref-type="fig"}). *O*-GlcNAcylation of CNS proteins important for axonal and synaptic function is significantly reduced in animal models of neurodegenerative diseases and in patient tissue from diseases including Parkinson's disease, Huntington's disease, Alzheimer's disease and ALS ([@awz358-B33]; [@awz358-B34]; [@awz358-B28]; [@awz358-B17]).

![**Schematic overview of the biosynthesis and function of major gangliosides within the mammalian brain.** Lactosylceramide is synthesized at the cytoplasmic leaflet of the endoplasmic reticulum membrane from its ceramide precursor. *De novo*ceramide is transported to the Golgi apparatus and is converted to glycosphingolipids and sphingomyelin through the addition of saccharides and phosphocholine, respectively. Glycosphingolipids are transported in vesicles to the outer leaflet of the plasma membrane. Sialic acid-enriched glycosphingolipids form gangliosides which are anchored to the membrane via their ceramide-lipid moiety. Four major gangliosides comprise \>90% of total gangliosides within the brain. A-series gangliosides (red) are derived from GM3. B-series gangliosides (purple) are synthesized from GM3 by GD3 synthase (St8sia1). G = the 'ganglioside' core; the second letter designates the quantity of sialic acid residues; M = mono; D = di; T = tri. Gangliosides are essential to maintaining neuronal integrity with functions including, but not limited to, increasing the neuroprotective properties of astrocytes, stabilizing interactions between neurons and glia, enhancing neurite outgrowth and negatively regulating neuroinflammation through activation of the complement pathway.](awz358f1){#awz358-F1}

![***O*-GlcNAcylation is implicated the pathophysiology of neurodegenerative disease.** An overview of *O*-GlcNAcylation, a post-translational modification of *O*-GlcNAc, which has been implicated in neurodegenerative diseases Huntington's disease, Alzheimer's disease, Parkinson's disease and ALS. *O*-GlcNAcylation occurs predominantly in the brain and is regulated by the glycosyltransferases OGT and EOGT, which attach the *O*-GlcNAc moiety to acceptor proteins at specific serine/threonine residues via an *O*-linked glycosidic bond; OGT acts intracellularly whereas EOGT acts extracellularly on secreted and membrane proteins.](awz358f2){#awz358-F2}

Neurodegenerative diseases exhibit late age of onset and it is therefore assumed that genetic mutations are upstream of disease pathogenesis. As a result, the discovery of neurodegenerative disease-associated DNA mutations is a significant step towards identification of upstream therapeutic targets. We have recently discovered that mutations proximal to the substrate-binding site of glycosyltransferase 8 domain-containing 1 (GLT8D1) disrupt enzyme activity and are associated with familial ALS ([@awz358-B11]). Our work is the first evidence that dysfunction of a glycosyltransferase is sufficient to cause a neurodegenerative disease. Our data are consistent with an effect of GLT8D1 mutations on ganglioside synthesis. In support of this mechanism, we have demonstrated by immunocytochemistry that ALS-associated GLT8D1 mutations reduce membrane expression of glycosphingolipids, which include gangliosides, in human cells (unpublished data). Moreover, in this review we summarize previous literature linking genetic changes within glycosyltransferases to neurodegeneration, and provide new evidence that genetic mutations within EOGT are significantly associated with sporadic ALS making this another upstream therapeutic target.

Impaired ganglioside synthesis is linked to neurodegeration
===========================================================

Parkinson's disease
-------------------

Reduced glycosyltransferase expression and lowered ganglioside synthesis has been implicated in the pathogenesis of Parkinson's disease. A recent report described a reduction in gene expression of the glycosyltransferases *B3GALT4* and *ST3GAL2* in neuromelanin-containing neurons in the substantia nigra of patients with Parkinson's disease compared to control subjects ([@awz358-B43]). These genes are key players in the ganglioside biosynthesis pathway ([Fig. 1](#awz358-F1){ref-type="fig"}). It is proposed that reduced B3GALT4 and ST3GAL2 expression leads to vulnerability of dopaminergic neurons via aberrant ganglioside synthesis. Consistent with this hypothesis, the number of GM1 ganglioside-expressing cells in the Parkinson's disease substantia nigra are reduced ([@awz358-B49]), and levels of the major brain gangliosides---GM1, GD1a, GD1b and GT1b---are decreased in whole substantia nigra homogenates from patients with Parkinson's disease ([@awz358-B44]). Model systems provide evidence that dysfunction of ganglioside synthesis is a cause and not just an association of typical Parkinson's disease pathology: genetically engineered mice lacking major brain gangliosides display overt motor impairment with increasing age, which is accompanied by loss of dopaminergic neurons from the substantia nigra pars compacta and aggregation of α-synuclein ([@awz358-B49]).

Huntington's disease
--------------------

In a similar manner to Parkinson's disease, reduced expression of glycosyltransferases involved in ganglioside synthesis has also been described in the R6/1 mouse model of Huntington's disease and in human Huntington's disease patients ([@awz358-B12]). In this study \>80% of gene expression changes observed in the striatum of R6/1 mice were also observed in the post-mortem caudate of human Huntington's disease subjects. Overlapping genes were significantly enriched with glycosyltransferases involved in ganglioside synthesis including *ST3GAL5*, *ST8SIA3*, *B4GALNT1* and *ST3GAL2* ([Fig. 1](#awz358-F1){ref-type="fig"}). Consistent with impaired ganglioside synthesis, the same study reported reduced ganglioside concentrations within both the diseased human caudate and the mouse striatum. It should be noted that despite significant homology to *ST8SIA1*, which has a well described role in ganglioside biosynthesis ([Fig. 1](#awz358-F1){ref-type="fig"}), *ST8SIA3* is traditionally associated with *N*-glycosylation of secreted/membrane proteins within the CNS ([@awz358-B32]). Like gangliosides, *N*-glycosylated proteins are important for cell signalling.

Alzheimer's disease
-------------------

There is good evidence for perturbed ganglioside metabolism in patients with Alzheimer's disease, and in the development of amyloid-β pathology in particular ([@awz358-B3]). In contrast to the findings in Parkinson's disease and Huntington's disease, the key observation appears to be increased ganglioside synthesis. Elevated GM1, GM2 and GM3 levels have been reported in the cerebral cortices of Alzheimer's disease patients ([@awz358-B27]; [@awz358-B20]). Development of amyloid-β deposition is the defining pathology of Alzheimer's disease and within brains exhibiting early Alzheimer's disease pathology, a significant proportion of amyloid-β is bound to ganglioside species ([@awz358-B53]). It has even been suggested that insoluble GM1-bound amyloid-β is the key toxin leading to neuronal death ([@awz358-B22]), as a result of high affinity binding between GM1 and amyloid-β, which facilitates formation of insoluble β-pleated sheets ([@awz358-B51]). With increasing age GM1 is localized to presynaptic nerve terminals and this may have a role in directing amyloid-β deposition to the same locations ([@awz358-B52]). Unlike evidence regarding gangliosides, reports of altered glycosyltransferase expression in Alzheimer's disease are more limited. There is evidence that glycosyltransferase activity may modify Alzheimer's disease pathology: overexpression of the glycosyltransferase B4GALNT1 leads to increased ganglioside expression but also increases APP cleavage to form amyloid-β pathology through suppression of lysosomal degradation of BACE1 ([@awz358-B50]). Currently, transgenic mouse models of Alzheimer's disease do not mirror changes in ganglioside distribution seen in human post-mortem tissue ([@awz358-B3]).

Amyotrophic lateral sclerosis
-----------------------------

ALS has been linked to abnormal lipid metabolism ([@awz358-B13]) and in particular, gangliosides and their ceramide precursors are thought to be modulators of disease progression ([@awz358-B42]; [@awz358-B45]). Whether ganglioside production is increased or decreased is controversial. As early as 1985 a 10% reduction in b-series gangliosides was identified within the motor cortex of ALS brains compared to non-ALS controls ([@awz358-B41]). More recently elevated levels of gangliosides GM1 and GM3 were reported within ALS post-mortem spinal cords compared to age-matched controls; findings were corroborated in the SOD1-G93A transgenic ALS mouse model ([@awz358-B14]). Interestingly, autoantibodies against specific gangliosides produce an inflammatory disease of spinal motor neurons known as multifocal motor neuropathy with conduction block ([@awz358-B21]), which is a frequent differential diagnosis of ALS.

ALS specifically inflicts pathology on the upper and lower motor neurons, the neuromuscular junction and muscle. The accessibility of this system in disease models facilitates the differentiation of up- and downstream disease associations. For example, increased expression of glycosphingolipids is observed in muscle tissue from end-stage mutant SOD1-ALS mice compared to controls, but similar changes were observed in response to surgically-induced muscle denervation suggesting a downstream effect ([@awz358-B23]). Moreover, neurotransmission at the neuromuscular junction is unchanged in aged GM2 and GD3-deficient mice compared to controls ([@awz358-B57]). However, our discovery that mutations in the glycosyltransferase GLT8D1 are a cause of familial ALS is a step forward, which places glycosyltransferase activity irrefutably upstream in the development of disease.

Genetic mutations in glycosyltransferases cause neurodegeneration
=================================================================

Genetic mutations in the development of an age-associated neurodegenerative disease are, by definition, upstream causes or risk factors rather than secondary to the disease process. Mutations discovered to date are included in [Table 1](#awz358-T1){ref-type="table"} and described below.

###### 

Defects affecting specific glycosyltransferase enzymes observed in neurodegenerative disease

  Glycosyltransferase   Functional consequence                                                           Neurodegenerative disorder                Defect observed                                                 Reference
  --------------------- -------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------ ----------------------------
  ST6GAL1               Disrupted cell surface signalling                                                Alzheimer's disease                       DNA mutations                                                 [@awz358-B31]
  B3GALT4               Reduced ganglioside biosynthesis (GD1b)                                          Parkinson's disease                       Reduced gene expression                                       [@awz358-B43]
  ST3GAL2               Reduced ganglioside biosynthesis (GT1b)                                          Parkinson's diseaseHuntington's disease   Reduced gene expression                                 [@awz358-B43][@awz358-B12]
  B4GALNT1              Reduced ganglioside biosynthesis                                                 Huntington's disease                      Reduced gene expression                                       [@awz358-B12]
  ST8SIA3               Implicated in ganglioside biosynthesis but described role in *N*-glycosylation   Huntington's disease                      Reduced gene expression                                       [@awz358-B12]
  ST3GAL5               Reduced ganglioside biosynthesis                                                 Huntington's disease                      Reduced gene expression                                       [@awz358-B12]
  GLT8D1                Reduced membrane expression of glycosphingolipids                                ALS                                       DNA mutations                                                 [@awz358-B11]
  UGT8                  Disruption of myelin synthesis                                                   ALS                                       DNA mutations                                                 [@awz358-B40]
  EOGT                  Disruption of *O*-GlcNAcylation                                                  ALS                                       DNA mutations                                                  This article
  OGT                   Impaired *O*-GlcNAcylation                                                       Alzheimer's diseaseALS                    Reduced concentration of *O*-GlcNAcylated proteins      [@awz358-B33][@awz358-B34]
  OGT                   Excessive *O*-GlcNAcylation                                                      Parkinson's disease                       Increased concentration of *O*-GlcNAcylated proteins          [@awz358-B48]

GLT8D1
------

A recent study from our lab demonstrated that mutations within the glycosyltransferase domain of *GLT8D1* are associated with familial ALS ([@awz358-B11]). The function of GLT8D1 is unknown, but it is ubiquitously expressed and localized to the Golgi apparatus. Based on sequence homology, GLT8D1 is a member of glycosyltransferase family 8 and is expected to catalyse the transfer of a glycosyl group from a donor to an acceptor via a 'retaining' mechanism. Mutated GLT8D1 carrying ALS-associated amino acid changes is toxic to neuronal and non-neuronal cell lines, and induces motor deficits in zebrafish embryos; these observations are consistent with a role in motor neuron degeneration. Interestingly, relative toxicity of ALS-associated mutations in model systems mirrors the clinical severity. Glycosyltransferase enzyme activity is reduced in the mutated form of GLT8D1 commensurate with an increase in substrate affinity, which is predicted to impair cycling of substrate through the enzyme and thus reduce overall velocity ([@awz358-B11]). Taken together, these data are consistent with loss-of-function toxicity. Our study is the first time inherited mutations that diminish glycosyltransferase enzyme activity have been associated with ALS. We have recently demonstrated by immunocytochemistry that ALS-associated mutations reduce membrane expression of glycosphingolipids in human cells (unpublished data). Glycosphingolipids include gangliosides and this would be consistent with disruption of ganglioside signalling within the CNS. GLT8D1 was recently identified as a risk gene for schizophrenia ([@awz358-B54]), and while schizophrenia is not a neurodegenerative disorder, it is noteworthy that ALS and schizophrenia share common genetic risk ([@awz358-B35]).

UDP glycosyltransferase 8 (*UGT8*)
----------------------------------

Like GLT8D1, UGT8 is a member of glycosyltransferase family 8. UGT8 functions in the biosynthesis of galactocerebroside, a sphingolipid that forms the myelin membrane in the central and peripheral nervous systems. Rare and potentially pathogenic copy number variants have been identified in the promotor region of *UGT8* following in an unbiased genome-wide screen for *de novo* DNA mutations in 12 trios including sporadic ALS patients and unaffected parents ([@awz358-B40]). Abnormal lipid biosynthesis and metabolism is a pathological hallmark of ALS ([@awz358-B16]; [@awz358-B15]), therefore it is possible that UGT8 plays a role in the hypolipidaemia observed in ALS patients and the SOD1-G93A ALS mouse model ([@awz358-B25]; [@awz358-B55]). Mice lacking *Ugt8a*, the orthologue of *UGT8*, exhibit impaired locomotor activity and disruption in nerve conduction followed by degeneration of the myelin sheath ([@awz358-B5]; [@awz358-B9]), which is rescued following transgenic expression of UGT8A ([@awz358-B58]). Interestingly the rescue occurred with expression of UGT8A under a promoter exclusively expressed within oligodendrocytes, which is consistent with other evidence implicating these cells in ALS-associated neurodegeneration ([@awz358-B36]).

ST6 β-galactoside α-2,6-sialyltransferase 1 (*ST6GAL1*)
-------------------------------------------------------

ST6GAL1 is an 'inverting' enzyme and a member of glycosyltransferase family 29. ST6GAL1 catalyses the transfer of sialic acid onto galactose-containing substrates including cell-surface signalling lipids and proteins ([@awz358-B18]). A genome-wide association study implicated polymorphisms within ST6GAL1 in the conversion of mild cognitive impairment into clinical Alzheimer's disease ([@awz358-B31]). Interestingly ST6GAL1 is cleaved and occurs in a soluble form; this cleavage is mediated by BACE1 ([@awz358-B26]), which is also involved in the cleavage of APP to form amyloid-β. Indeed, overexpression of ST6GAL1 increases APP secretion ([@awz358-B37]) suggesting that the activity of ST6GAL1 can directly modify the central pathway in the development of Alzheimer's pathology.

Glycosyltransferase *O*-GlcNAcylation: a key regulator of neurodegeneration?
============================================================================

Protein glycosylation and more specifically the addition of *O*-GlcNAc groups to CNS proteins important for axonal and synaptic function, is significantly reduced in animal models of neurodegenerative diseases and in patient tissue from diseases including Huntington's disease, Alzheimer's disease and ALS ([@awz358-B33]; [@awz358-B34]; [@awz358-B28]; [@awz358-B17]) ([Table 1](#awz358-T1){ref-type="table"}). *O*-GlcNAcylation is reported to negatively regulate tau phosphorylation ([@awz358-B33]), which is key in the pathogenesis of a number of neurodegenerative diseases, including Alzheimer's disease. In contrast, an increase in *O*-GlcNAcylation is observed in the post-mortem temporal cortex of patients with Parkinson's disease and is postulated to contribute to neurodegeneration through the inhibition of autophagy leading to an increase in α-synuclein accumulation ([@awz358-B48]). Neurofilaments are critical components of the neuronal cytoskeleton that can undergo *O*-GlcNAcylation ([@awz358-B56]). Neurofilament levels are significantly higher in the serum and CSF of ALS patients compared to control subjects ([@awz358-B4]). This increase is thought to be a consequence of axonal damage. However, there is evidence that neurofilament damage may be upstream in the pathogenesis of ALS including the observation that increased phosphorylation of neurofilaments is associated with neurotoxicity ([@awz358-B24]). It is thought that phosphorylation and *O*-GlcNAcylation are reciprocal, meaning that reduced *O*-GlcNAcylation could precipitate harmful phosphorylation; indeed this has been observed in a transgenic rat model of SOD1-ALS ([@awz358-B34]).

*O*-GlcNAcylation occurs predominantly in the brain and is regulated by the glycosyltransferases OGT and EOGT; the reverse reaction is catalysed by *O*-GlcNAcase (OGA). Together these reactions constitute a dynamic and reversible process ([Fig. 2](#awz358-F2){ref-type="fig"}). OGT is an inverting enzyme and a member of glycosyltransferase family 41; OGT is highly enriched in the brain, where it is 10 times more active than in peripheral tissue ([@awz358-B39]). OGT is localized to the nucleus, soma, dendrites and presynaptic terminals of neurons ([@awz358-B1]). Removal of postsynaptic OGT from primary neurons inhibits both synapse formation and the development of dendritic spines ([@awz358-B29]). This highlights the importance of OGT in maintaining synaptic stability, and notably loss of synaptic stability is a unifying feature of neurodegenerative disease. EOGT is an inverting enzyme and a member of glycosyltransferase family 61. Despite distinct sites of action, OGT and EOGT are both regulated via the hexosamine biosynthetic pathway ([@awz358-B38]). EOGT activity is involved in Notch signalling, which is important for neurodevelopment. Indeed, homozygous loss-of-function mutations in EOGT produce Adams-Oliver syndrome, a congenital developmental disorder associated with actin cytoskeleton defects.

ALS-associated genetic variants within *O*-GlcNAcylation pathway enzymes
------------------------------------------------------------------------

While homozygous EOGT mutations affect neurodevelopment, we hypothesized that heterozygous mutations within EOGT might negatively impact on the maintenance of axon integrity and increase risk of developing ALS. To test this hypothesis we performed rare-variant burden testing ([@awz358-B8]) within EOGT to check for a genetic association with ALS. We used whole genome sequencing data from 4493 sporadic ALS patients and 1924 control subjects ([@awz358-B47]); we identified 32 missense rare (MAF \< 1%) variants within EOGT that were exclusively or predominantly found in ALS cases ([Table 2](#awz358-T2){ref-type="table"}). When considering all rare missense variants found in cases and controls across all exons of EOGT, there was a significant enrichment of such mutations in ALS patients (Firth logistic regression, *P* = 0.007). Similar testing did not identify an enrichment of ALS-associated mutations within OGT, indeed we only identified two rare missense mutations within OGT in 4493 sporadic ALS patients. It should be noted that OGT is encoded on the X chromosome and therefore males are necessarily hemizygous, which may predispose to a neurodevelopmental phenotype rather than a late age-of-onset disease: for example mutations within N-terminal tetratricopeptide repeats of OGT are associated with X-linked intellectual disability ([@awz358-B19]). There was no significant burden of ALS-associated mutations within OGA (*P* = 0.91).

###### 

Mutations in EOGT found in ALS patients

  DNA change   Protein change   Allele frequency     Exon   
  ------------ ---------------- ------------------ -------- ----
  c.1575T\>G   p.Asp525Glu      0.001               0.0005  15
  c.1546C\>T   p.Pro516Ser      0.0001                0     15
  c.1466C\>T   p.Pro489Leu      0.0001                0     15
  c.1459dupG   p.Glu487fs       0.0001                0     15
  c.1456G\>T   p.Gly486Trp      0.0001                0     15
  c.1432G\>A   p.Asp478Asn      0.0001                0     14
  c.1417A\>T   p.Lys473\*       0.0001                0     14
  c.1355G\>A   p.Arg452His      0.0001                0     14
  c.1342T\>A   p.Cys448Ser      0.0001                0     14
  c.1256C\>T   p.Thr419Met      0.0001                0     13
  c.1213A\>G   p.Arg405Gly      0.01                0.006   12
  c.1210T\>A   p.Tyr404Asn      0.0001                0     12
  c.1129C\>T   p.Arg377Trp      0.0001                0     11
  c.1114C\>T   p.Arg372Trp      0.0001                0     11
  c.1108C\>T   p.Leu370Phe      0.0001                0     11
  c.829A\>G    p.Thr277Ala      0.0001                0     10
  c.692T\>C    p.Ile231Thr      0.0001                0     9
  c.674C\>T    p.Ala225Val      0.0001                0     9
  c.647A\>G    p.Gln216Arg      0.0001                0     9
  c.563A\>T    p.Lys188Ile      0.0002                0     8
  c.562A\>T    p.Lys188\*       0.0002                0     8
  c.430A\>G    p.Ser144Gly      0.0002                0     7
  c.314C\>T    p.Thr105Met      0.0001                0     6
  c.208A\>G    p.Lys70Glu       0.0001                0     4
  c.202C\>G    p.Pro68Ala       0.0001                0     4
  c.192C\>G    p.Asp64Glu       0.0001                0     4
  c.176C\>G    p.Thr59Ser       0.0005              0.0003  4
  c.169A\>G    p.Ile57Val       0.0001                0     4
  c.155A\>G    p.His52Arg       0.0002                0     4
  c.122G\>T    p.Arg41Leu       0.0002                0     4
  c.71C\>G     p.Pro24Arg       0.0007              0.0003  4
  c.9G\>A      p.Met3Ile        0.0001                0     4

ALS-associated missense changes found within EOGT in 4493 sporadic ALS patients and 1924 controls. Mutations are listed 5' to 3'; EOGT has 15 exons and is encoded on the reverse strand of chromosome 3; exons 1 to 3 are non-coding.

Conclusions
===========

Overall there is substantial evidence for dysfunction of glycosyltransferases in neurodegenerative diseases including ALS, Alzheimer's disease, Huntington's disease and Parkinson's disease. There are diverse functions associated with glycosyltransferase activity and for many of the enzymes the biological pathway associated with their activity is not yet clear. However, in our analysis, dysfunction associated with neurodegenerative disease can be seen to converge on the ganglioside synthesis pathway and altered *O*-GlcNAcylation. The exact nature of the defect appears to be variable in different diseases; for example ganglioside concentrations are reduced in Parkinson's disease and Huntington's disease, increased in Alzheimer's disease and there is evidence for change in both directions in ALS. Similarly, increased *O*-GlcNAcylation is associated with the development of Parkinson's disease pathology but reduced *O*-GlcNAcylation is associated with the development of tau pathology. We suggest that consensus will arise via efforts to position glycosyltransferase dysfunction within the cascade of pathogenesis leading to neuronal death---it is not glycosyltransferase dysfunction *per se* that is interesting, but rather upstream changes in glycosyltransferase function that initiate toxicity. With this in mind we have highlighted genetic associations between mutations in glycosyltransferases and neurodegenerative disease. Most prominently we have recently discovered autosomal dominant mutations in GLT8D1 to be a monogenic cause of ALS. Disease-associated mutations have also been discovered in UGT8 and ST6GAL1; and we have revealed a new association between ALS and mutations in EOGT. Glycosyltransferases are likely to be an important therapeutic target in the effort of develop disease-modifying therapies for neurodegenerative disease.
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